You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics prior to initial brain irradiation

From: Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era

Patient Characteristics n =441 n =37
Age (years)   
   Median 55 48
Grade, primary tumor   
   1 13 (3%) 1 (3%)
   2 106 (24%) 13 (35%)
   3 315 (71%) 22 (59%)
   Unknown 7(2%) 1 (3%)
Hormone receptor status, primary tumor   
   ER+ 180 (41%) 14 (38%)
   ER- 249 (56%) 22 (60%)
   Unknown 12 (3%) 1 (2%)
HER2 status, primary tumor   
   Positive 176 (40%) 26 (70%)
   Negative 212 (48%) 7 (19%)
   Unknown 53 (12%) 4 (11%)
KPS at first BM   
   < 70 170 (38%) 10 (27%)
   ≥ 70 271 (61%) 27 (73%)
ECOG at first BM   
   0-1 109 (25%) 21 (57%)
   2 186 (42%) 13 (35%)
   3-4 146 (33%) 3 (8%)
Number of lesions   
   1-3 190 (43%) 21 (57%)
   > 3 251 (57%) 16 (43%)
Primary status   
   Controlled 305 (69%) 28 (76%)
   Uncontrolled 135 (31%) 9 (24%)
Extracranial disease   
   Brain only 97 (22%) 19 (51%)
   Bone + brain 76 (17%) 6 (16%)
   Visceral + brain 245 (56%) 12 (32%)
   Other 23 (5%) 0 (0%)
RPA at first BM   
   1 55 (12%) 11 (30%)
   2 219 (50%) 16 (43%)
   3 167 (38%) 10 (27%)
Hormonal therapy at BM*   
   Yes 100 (23%) 14 (38%)
   No 341 (77%) 23 (62%)
Chemotherapy at BM*   
   Yes 194 (44%) 29 (78%)
   No 242 (55%) 8 (22%)
Trastuzumab at BM*   
   Yes 136 (31%) 21 (57%)
   No 305 (69%) 16 (43%)
Trastuzumab†   
   Yes 157 (36%) 25 (67%)
   No 284 (64%) 12 (32%)
Craniotomy   
   Yes 87 (20%) 16 (43%)
   No 354 (80%) 21 (57%)
  1. * Refers to treatments given on or after the date of first brain metastases.
  2. †Trastuzumab use at any point including those within 90 days of brain metastases.
  3. Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, BM = brain metastasis, KPS = karnofsky performance status, ECOG = eastern cooperative oncology group, RPA = recursive partitioning analysis